CKD-704

risankizumab · Chong Kun Dang Pharmaceutical

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CKD-704, covering 2025-12-19 to 2025-12-19. Get the full timeline:

Most recent: Clinical Trial Update: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants [Phase 1]

See pricing